18F-FMISO PET-guided dose escalation with multifield optimization intensity-modulated proton therapy in nasopharyngeal carcinoma.

PURPOSE The purpose of this study was to evaluate the radiotherapy planning feasibility of dose escalation with intensity-modulated proton therapy (IMPT) to hypoxic tumor regions identified on 18F-Fluoromisonidazole (FMISO) positron emission tomography and computed tomography (PET-CT) in NPC. MATERIALS AND METHODS Nine patients with stages T3-4N0-3M0 NPC underwent 18F-FMISO PET-CT before and during week 3 of radiotherapy. The hypoxic volume (GTVhypo) is automatically generated by applying a subthresholding algorithm within the gross tumor volume (GTV) with a tumor to muscle standardized uptake value (SUV) ratio of 1.3 on the 18F-FMISO PET-CT scan. Two proton plans were generated for each patient, a standard plan to 70 Gy and dose escalation plan with upfront boost followed by standard 70GyE plan. The stereotactic boost was planned with single-field uniform dose optimization using two fields to deliver 10 GyE in two fractions to GTVhypo. The standard plan was generated with IMPT with robust optimization to deliver 70GyE, 60GyE in 33 fractions using simultaneous integrated boost technique. A plan sum was generated for assessment. RESULTS Eight of nine patients showed tumor hypoxia on the baseline 18F-FMISO PET-CT scan. The mean hypoxic tumor volume was 3.9 cm3 (range .9-11.9cm3 ). The average SUVmax of the hypoxic volume was 2.2 (range 1.44-2.98). All the dose-volume parameters met the planning objectives for target coverage. Dose escalation was not feasible in three of eight patients as the D0.03cc of temporal lobe was greater than 75GyE. CONCLUSIONS The utility of boost to the hypoxic volume before standard course of radiotherapy with IMPT is dosimetrically feasible in selected patients. Clinical trials are warranted to determine the clinical outcomes of this approach.

[1]  E. Sierko,et al.  Usefulness of Hybrid PET/MRI in Clinical Evaluation of Head and Neck Cancer Patients , 2020, Cancers.

[2]  G. Kayser,et al.  Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy—results from a prospective trial , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  N. Lee,et al.  Hypoxia with 18F-fluoroerythronitroimidazole integrated positron emission tomography and computed tomography (18F-FETNIM PET/CT) in locoregionally advanced head and neck cancer , 2019, Medicine.

[4]  R. Modzelewski,et al.  Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [18F]FDG and [18F]Fluoromisonidazole PET/CT in Non-small-cell Lung Cancer Patients , 2019, Molecular Imaging and Biology.

[5]  George E. Laramore,et al.  Clinical Monte Carlo versus Pencil Beam Treatment Planning in Nasopharyngeal Patients Receiving IMPT. , 2019, International journal of particle therapy.

[6]  S. Hung,et al.  Intensity-Modulated Proton Therapy Reduces Acute Treatment-Related Toxicities for Patients with Nasopharyngeal Cancer: A Case-Control Propensity Score Match Study with Volumetric Modulated Arc Therapy , 2018, International Journal of Radiation Oncology, Biology, Physics.

[7]  Xiangpeng Zheng,et al.  18F‐Fluoromisonidazole positron emission tomography/CT‐guided volumetric‐modulated arc therapy‐based dose escalation for hypoxic subvolume in nasopharyngeal carcinomas: A feasibility study , 2017, Head & neck.

[8]  K. Nikolaou,et al.  Geometric analysis of loco-regional recurrences in relation to pre-treatment hypoxia in patients with head and neck cancer , 2017, Acta oncologica.

[9]  Yoichi M. Ito,et al.  Local relapse of nasopharyngeal cancer and Voxel-based analysis of FMISO uptake using PET with semiconductor detectors , 2017, Radiation oncology.

[10]  M. Alber,et al.  Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  A. Garden,et al.  Intensity‐modulated proton therapy for nasopharyngeal carcinoma: Decreased radiation dose to normal structures and encouraging clinical outcomes , 2016, Head & neck.

[12]  Tyler J. Fraum,et al.  PET/MRI: Emerging Clinical Applications in Oncology. , 2016, Academic radiology.

[13]  Werner Vach,et al.  Serial [18F]-fluoromisonidazole PET during radiochemotherapy for locally advanced head and neck cancer and its correlation with outcome. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  Allan Hanbury,et al.  Metrics for evaluating 3D medical image segmentation: analysis, selection, and tool , 2015, BMC Medical Imaging.

[15]  Anne Bol,et al.  Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: A planning study , 2015, Acta oncologica.

[16]  Longzhen Zhang,et al.  A Randomized Pilot Trial Comparing Position Emission Tomography (PET)-Guided Dose Escalation Radiotherapy to Conventional Radiotherapy in Chemoradiotherapy Treatment of Locally Advanced Nasopharyngeal Carcinoma , 2015, PloS one.

[17]  T. Lu,et al.  Local failure patterns for patients with nasopharyngeal carcinoma after intensity-modulated radiotherapy , 2014, Radiation oncology.

[18]  V. Grégoire,et al.  A prospective clinical study of 18 F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  H. Ying,et al.  Patterns of local-regional failure after primary intensity modulated radiotherapy for nasopharyngeal carcinoma , 2014, Radiation oncology.

[20]  V. Khoo,et al.  Hypoxia-targeted radiotherapy dose painting for head and neck cancer using 18F-FMISO PET: A biological modeling study , 2013, Acta oncologica.

[21]  K. Krohn,et al.  Local Recurrence and Progression Is Spatially Correlated With Focal Pretreatment FMISO PET Uptake in Head and Neck SCC , 2013 .

[22]  R. Mohan,et al.  New Strategies in Radiation Therapy: Exploiting the Full Potential of Protons , 2013, Clinical Cancer Research.

[23]  J. Yi,et al.  Fractionated stereotactic radiotherapy for 136 patients with locally residual nasopharyngeal carcinoma , 2013, Radiation Oncology.

[24]  Arjen van der Schaaf,et al.  The potential of intensity-modulated proton radiotherapy to reduce swallowing dysfunction in the treatment of head and neck cancer: A planning comparative study , 2013, Acta oncologica.

[25]  C. Cao,et al.  Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for T4 nasopharyngeal carcinoma. , 2013, Oral oncology.

[26]  E. Hui,et al.  Targeting tumor hypoxia in nasopharyngeal carcinoma , 2013, Head & neck.

[27]  Wade P. Smith,et al.  Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  A. Lee,et al.  Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. , 2011, International journal of radiation oncology, biology, physics.

[29]  J. Humm,et al.  Correlation of 18F-Fluoromisonidazole Positron Emission and Computed Tomography (18F-FMISO PET/CT) with Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE MRI) in Assessing Tumor Hypoxia in Head and Neck Cancer(HNC) Patients with Nodal Metastases , 2009 .

[30]  C. Ling,et al.  Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. , 2009, International journal of radiation oncology, biology, physics.

[31]  Riccardo Calandrino,et al.  Intensity-modulated proton therapy versus helical tomotherapy in nasopharynx cancer: planning comparison and NTCP evaluation. , 2008, International journal of radiation oncology, biology, physics.

[32]  Uwe Oelfke,et al.  Radiation Oncology Intensity-modulated Radiotherapy of Nasopharyngeal Carcinoma: a Comparative Treatment Planning Study of Photons and Protons , 2022 .

[33]  J. Sham,et al.  Outcome of fractionated stereotactic radiotherapy for 90 patients with locally persistent and recurrent nasopharyngeal carcinoma. , 2007, International journal of radiation oncology, biology, physics.

[34]  Daniela Thorwarth,et al.  Hypoxia dose painting by numbers: a planning study. , 2007, International journal of radiation oncology, biology, physics.

[35]  David L. Schwartz,et al.  Tumor Hypoxia Imaging with [F-18] Fluoromisonidazole Positron Emission Tomography in Head and Neck Cancer , 2006, Clinical Cancer Research.

[36]  W. Oyen,et al.  Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  Martin Westhofen,et al.  FDG—a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[38]  Chong Zhao,et al.  [Clinical application of 99mTc-HL91 hypoxia imaging in nasopharyngeal carcinoma]. , 2006, Ai zheng = Aizheng = Chinese journal of cancer.

[39]  J. Sham,et al.  Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. , 2006, International journal of radiation oncology, biology, physics.

[40]  Hazim Jaradat,et al.  Integral radiation dose to normal structures with conformal external beam radiation. , 2005, International journal of radiation oncology, biology, physics.

[41]  Lester J. Peters,et al.  Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[42]  M. Eble,et al.  pO2 Polarography Versus Positron Emission Tomography ([18F] Fluoromisonidazole, [18F]-2-Fluoro-2’-Deoxyglucose) , 2004, Strahlentherapie und Onkologie.

[43]  J. Eary,et al.  [18F]FMISO and [18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[44]  Richard A Popple,et al.  Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. , 2002, International journal of radiation oncology, biology, physics.

[45]  K. Krohn,et al.  Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. , 1989, International journal of radiation oncology, biology, physics.

[46]  L. R. Dice.  Measures of the Amount of Ecologic Association Between Species , 1945 .

[47]  W. Oyen,et al.  Correlation of [18F]FMISO autoradiography and pimonidazole immunohistochemistry in human head and neck carcinoma xenografts , 2008, European Journal of Nuclear Medicine and Molecular Imaging.